Cytosorbents Corporation (CTSO) Stock

Healthcare · Medical Devices · Member of Other US Stocks

Cytosorbents Corporation (CTSO) closed at USD 3.09 on 2026-10-14, a change of -81.5 % over the past year, with a market capitalization of USD 9.64M.

Cytosorbents Corporation recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Cytosorbents Corporation key figures

Previous close

USD 3.09 (2026-10-14)

1-year change

-81.5 %

Market cap

USD 9.64M

Enterprise value

USD 34.63M

P/E ratio (trailing)

-0.60

P/E ratio (forward)

n/a

EPS (trailing)

-5.13

EPS (forward)

0.00

PEG ratio

n/a

Price to book

-12.80

Revenue growth

0.2 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.71

Employees

129

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Cytosorbents Corporation

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Cytosorbents Corporation and compare it with other stocks.